Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 33581 for:    value

Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study (VALUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03576937
Recruitment Status : Recruiting
First Posted : July 4, 2018
Last Update Posted : July 4, 2019
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
Current guidelines in non-small cell lung cancer recommend genomic assessment for mutations in EGFR and BRAF, gene rearrangements in ALK and ROS1, and resistance mutations such as T790M upon progression during EGFR inhibitor therapy. However, obtaining sufficient tumour tissue to test for these molecular alterations, as well as those with emerging targeted therapies, is challenging in lung cancer. A promising method to improve molecular diagnostic testing in lung and other cancers is the use of circulating cell-free DNA (cfDNA) obtained from blood samples or liquid biopsies. This multi-centre prospective study will compare blood-based profiling (using the GUARDANT360 assay) to standard of care tissue-based profiling within the Canadian system.

Condition or disease Intervention/treatment
Non-small Cell Lung Cancer Diagnostic Test: GUARDANT360

Layout table for study information
Study Type : Observational
Estimated Enrollment : 210 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study
Actual Study Start Date : February 12, 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Cohort 1
Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
Diagnostic Test: GUARDANT360
GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.

Cohort 2
Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
Diagnostic Test: GUARDANT360
GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.




Primary Outcome Measures :
  1. Response rate to first-line therapy [ Time Frame: Up to 18 Months ]
    Measure best response to first-line therapy using investigator-assessed RECIST 1.1, including progression free survival and time to treatment failure, in patients with advanced lung adenocarcinoma using the cfDNA GUARDANT360 assay versus standard of care tissue genotyping.


Secondary Outcome Measures :
  1. Proportion of patients receiving targeted therapy [ Time Frame: Up to 18 Months ]
    Compare the proportion of patients receiving targeted therapy using the cfDNA GUARDANT360 assay versus standard of care tissue genotyping.

  2. Time to Treatment Initiation [ Time Frame: Up to 18 Months ]
    The time to treatment initiation using both genotyping methods, will be calculated as the number of days from the date of pathologic or clinical stage IV NSCLC diagnosis until initiation of systemic treatment. This will be compared to the turnaround time for GUARDANT360 results.

  3. Incremental number of actionable genomic alterations [ Time Frame: Up to 18 Months ]
    Count the number of actionable genomic alterations identified in cfDNA that were not identified in tumour tissue standard of care testing.

  4. Turnaround time of cfDNA vs. tissue results [ Time Frame: Up to 18 Months ]
    Calculate the time (in days) from the date of request for testing to the report date for both genotyping methods.

  5. Costs of cfDNA vs. tissue testing [ Time Frame: Up to 18 Months ]
    Cost consequence analysis to examine incremental mean direct and indirect costs in Canadian dollars between the two approaches (cfDNA testing vs tumour tissue genotyping).


Other Outcome Measures:
  1. Response rate to immunotherapy [ Time Frame: Up to 18 Months ]
    Assess response rate in patients (Cohort 1) who received single agent or combination immunotherapy.

  2. Response duration to immunotherapy [ Time Frame: Up to 18 Months ]
    Assess response duration in patients (Cohort 1) who received single agent or combination immunotherapy.

  3. Patient reported quality of life [ Time Frame: Upon entry and 3 months following initiation of systemic therapy ]
    Patient quality of life will be measured using the EQ5D-5L, which will be administered upon entry to the study and 3 months after starting systemic therapy.

  4. Patient willingness-to-pay [ Time Frame: Within 30 days of study enrollment ]
    Evaluate patient willingness-to-pay for using a next generation sequencing assay, such as the GUARDANT360, using a validated patient survey.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Non-small cell lung cancer patients (Stage IIIB or IV not eligible for curative intent treatment, or relapsed/recurrent disease)
Criteria

Inclusion Criteria:

Patients with non-small cell lung cancer (NSCLC) with:

  1. Histologically-proven, advanced (Stage IIIB or IV not eligible for curative intent treatment, or relapsed/recurrent) disease;
  2. Non-squamous histology (mixed adenocarcinoma histology is allowed);
  3. Never smoking or light smoking history (≤10 pack years);
  4. Measureable disease by RECIST 1.1;
  5. Patients who have previously received curative therapy are eligible if primary treatment was completed at least 6 months prior to the development of advanced disease; for patients who received adjuvant systemic therapy, the last dose of treatment must have been given at least 6 weeks prior to enrollment;
  6. Age ≥ 18 years;
  7. Ability to provide written informed consent;
  8. Agreement to provide blood sample prior to starting systemic treatment;
  9. Eligibility for targeted therapy in the opinion of the investigator;
  10. Standard-of-care tissue genotyping ordered or planned. Patients with tissue deemed insufficient for genotyping are eligible.
  11. Cohort 2 only: evidence of disease progression on prior targeted tyrosine kinase inhibitor or other targeted therapy for EGFR including T790M, ALK, ROS-1 or BRAF-deranged advanced NSCLC. Patients progressing on 1st or 2nd generation EGFR TKI must have undergone SOC testing for EGFR T790M. If blood- or tissue-negative for T790M, the patient is eligible for this study. If T790M-positive, the patient must have progressed on a T790M inhibitor to be eligible. Intervening systemic therapy such as chemotherapy or immunotherapy is permitted.

Exclusion Criteria:

  1. Pregnancy;
  2. ≥10 pack year smoking history;
  3. Any other concurrent malignancy except for localized, non-melanoma, cutaneous cancer or non-invasive cervical cancer. Any prior cancer other than NSCLC must have occurred more than 2 years prior to study entry with no evidence of currently active disease;
  4. Prior resection of metastatic disease if the resected metastasis was the only site of measurable disease;
  5. Radiation of a metastatic lesion or residual disease if administered to the only site(s) of advanced disease;
  6. Cohort 1 only: Prior systemic treatment for metastatic NSCLC including but not limited to targeted therapy, chemotherapy, immunotherapy, or biologic therapy. Adjuvant therapy is permitted at least 6 weeks prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03576937


Contacts
Layout table for location contacts
Contact: Jennifer Law (Research Manager) 416-946-2259 Jennifer.Law@uhn.ca

Locations
Layout table for location information
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada
Principal Investigator: Desiree Hao, MD         
Canada, British Columbia
BC Cancer Agency Not yet recruiting
Vancouver, British Columbia, Canada
Principal Investigator: Janessa Laskin, MD         
Canada, Ontario
Juravinski Cancer Centre Recruiting
Hamilton, Ontario, Canada
Principal Investigator: Rosalyn Jeurgens, MD, PhD         
Ottawa Hospital Regional Cancer Centre Recruiting
Ottawa, Ontario, Canada
Principal Investigator: Scott Laurie, MD         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada
Principal Investigator: Natasha Leighl, MD         
Canada, Quebec
Jewish General Hospital Recruiting
Montreal, Quebec, Canada
Principal Investigator: Jason Agulnik, MD         
Sponsors and Collaborators
University Health Network, Toronto

Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT03576937     History of Changes
Other Study ID Numbers: 18-5353
First Posted: July 4, 2018    Key Record Dates
Last Update Posted: July 4, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases